IGFBP2 and neoplasm: In a previous study investigating the chemoresistance mechanism in EAC, MEK inhibitors including selumetinib and trametinib were shown to enhance cisplatin-induced cytotoxicity when combined with IGFBP2 knockdown, which reflects that MEK signaling could be a promising strategy to overcome this resistance depending on the tumor microenvironment [59].